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NF-jB and STAT3 Inhibition as a Therapeutic Strategy
in Psoriasis: In Vitro and In Vivo Effects of BTH
Rosa M. Andre´s1,2, M. Carmen Montesinos1,2, Pedro Navalo´n3, Miguel Paya´1,2 and M. Carmen Terencio1,2
Benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one (BTH) is a simple and interesting synthetic derivative
of petrosaspongiolide M, a natural compound isolated from a sea sponge with demonstrated potent anti-
inflammatory activity through inhibition of the NF-kB signaling pathway. In the present study, we report the
in vitro and in vivo pharmacological effect of BTH on some parameters related to the innate and adaptive
response in the pathogenesis of psoriasis. BTH inhibited the release of some of the key psoriatic cytokines such
as tumor necrosis factor a, IL-8, IL-6, and CCL27 through the downregulation of NF-kB in normal human
keratinocytes. Moreover, it impaired signal transducers and activators of transcription 3 (STAT3) phosphorylation
and translocation to the nucleus, which resulted in decreased keratinocyte proliferation. These results were
confirmed in vivo in two murine models of psoriasis: the epidermal hyperplasia induced by 12-O-tetradecanoyl-
phorbol-13-acetate and the imiquimod-induced skin inflammation model. In both cases, topical administration of
BTH prevented skin infiltration and hyperplasia through suppression of NF-kB and STAT3 phosphorylation. Our
results confirm the pivotal role of both transcriptional factors in skin inflammation, as occurs in psoriasis, and
highlight the potential of small molecules as therapeutic agents for the treatment of this skin disease, with BTH
being a potential candidate for future drug research.
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INTRODUCTION
Psoriasis is a common immune-mediated inflammatory skin
disorder affecting 2–3% of the population. It is characterized
by infiltrating leukocytes that release growth factors, cyto-
kines, and chemokines affecting epidermal keratinocyte
proliferation and differentiation. Although genetic and envir-
onmental factors have a role in the etiology of psoriasis, a
common set of effectors are involved in the characteristic
manifestations of this skin pathology. Therefore, the onset of
psoriatic lesions could be inhibited by abrogation of the
transcriptional factors that trigger these mechanisms. This
therapeutic strategy has been postulated for signal transducers
and activators of transcription 3 (STAT3) and NF-kB (Miyoshi
et al., 2011; Perera et al., 2012).
Increased phosphorylation of STAT3 (pSTAT3) has been
demonstrated in lesional skin of psoriatic patients and trans-
genic mice expressing constitutively active STAT3 in their
keratinocytes develop skin lesions strikingly similar to human
psoriatic plaques (Sano et al., 2005). Moreover, several
cytokines and growth factors upregulated in psoriasis, such
as IL-6 and the IL-20 family cytokines, signal through STAT3
activation (Grossman et al., 1989; Sa et al., 2007; Wolk et al.,
2009). STAT3 regulates the expression of genes controlling
survival, proliferation, and angiogenesis through collaboration
with other transcription factors, including NF-kB (Aggarwal
et al., 2009). In addition, STAT3 has been shown to have
a role in the psoriasis-associated IL-23 signaling pathway
(Di Cesare et al., 2009).
NF-kB is a crucial factor in the immune-inflammatory
responses implicated in various skin diseases, including
psoriasis. In fact, several antipsoriatic drugs act in part by
inhibition of this nuclear factor (Perera et al., 2012).
Furthermore, upregulation of NF-kB activation in lesional
psoriatic skin compared with nonlesional psoriatic skin has
been demonstrated (Lizzul et al., 2005). Activation of the
NF-kB pathway leads to the transcription of numerous genes
including cytokines, chemokines, and growth factors that are
involved in the initiation of the inflammatory response (Perera
et al., 2012). Remarkably, NF-kB induces the production of
cytokines, such as tumor necrosis factor a (TNFa), which
further activate NF-kB, thus conforming a vicious cycle
(Quivy and Van Lint, 2004). In this way, an essential link
between TNFa levels and NF-kB activation has been found in
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psoriatic patients, and disease resolution after treatment with
TNFa-blocking agents correlated with downregulation of
NF-kB transcriptional activity (Gottlieb et al., 2005; Lizzul
et al., 2005).
Bioactive natural products are considered to be promising
prototypes for the development of new therapeutic agents, as
they are evolutionary selected and basically validated for
interfering with biological targets. Hence, libraries designed
and synthesized around the basic structure of such com-
pounds have a good chance of displaying biological and
pharmacological properties. On the basis of these remarks, a
series of analogs containing the g-hydroxybutenolide moiety
of the marine natural compound petrosaspongiolide M, a
potent anti-inflammatory agent that inhibits NF-kB activation
(Posadas et al., 2003), were synthesized (Guerrero et al., 2007;
De Simone et al., 2010). Among them, the synthetic derivative
4-benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one
(BTH) (Figure 1a) was characterized as a potent NF-kB
inhibitor in vitro (Guerrero et al., 2007), which exerted an
anti-inflammatory effect in both the acute murine air pouch
model and the chronic collagen-induced arthritis (Guerrero
et al., 2009).
Given the interesting anti-inflammatory profile and the
strong inhibition of NF-kB activation elicited by BTH, we
hypothesized that it might be effective in other chronic
inflammatory diseases such as psoriasis. In the present study,
we describe the pharmacological effect of BTH on the
activation and proliferation of human keratinocytes and its
efficacy after topical application in the murine models of
12-O-tetradecanoylphorbol 13-acetate (TPA)–induced hyper-
plasia and imiquimod (IMQ)-induced skin inflammation. The
potential antipsoriatic profile of BTH can be a consequence of
its inhibitory effect on the NF-kB and STAT3 pathways.
RESULTS
BTH inhibits NF-jB activation and proinflammatory cytokine
release in normal human keratinocytes
Our first goal was to assess whether BTH maintained its
mechanism of action in normal human keratinocytes (NHKs)
stimulated with the protein kinase C activator TPA, which
promotes NF-kB transcriptional activity, upregulating the
transcription of TNFa and other proinflammatory cytokines
(Cataisson et al., 2005). Preincubation for 30 minutes with
either BTH (1 and 10mM) or the proteasome inhibitor MG-132
(1mM) inhibited NF-kB-DNA binding in NHKs stimulated with
TPA (1mg ml1) for 1 hour (Figure 1b). Consequently, BTH
also reduced the release of TNFa and IL-8, cytokines that have
a pivotal role in psoriasis pathogenesis (Pietrzak et al., 2008),
after 7 hours of stimulation with TPA (Figure 1c).
We next characterized the effect of BTH on the release of
several cytokines induced by TNFa (10 ng ml 1). In 48 hours–
stimulated NHKs, BTH inhibited the production of IL-6, a
cytokine involved in the psoriatic epidermal hyperprolifera-
tion, and CCL27/CTACK (cutaneous T cell–attracting chemo-
kine), a keratinocyte-specific chemokine highly upregulated in
inflammatory skin diseases (Riis et al., 2011) (Figure 1d).
BTH impairs STAT3 translocation to the nucleus and decreases
keratinocyte proliferation in vitro
As shown in Figure 2a and b, an inhibition of IL-6-induced
STAT3 nuclear translocation was observed by immunofluor-
escence staining after a 30-minute pretreatment with BTH.
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Figure 1. Inhibitory effect of 4-benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one (BTH) on NF-jB activation and cytokine release in normal human
keratinocytes (NHKs). (a) Chemical structure of BTH. (b) NF-kB electrophoretic mobility shift assay of the nuclear extracts of cultured NHKs. Cells were
preincubated with BTH or the reference compound MG-132 (MG) for 30 minutes before 1 hour of 12-O-tetradecanoylphorbol-13-acetate (TPA) stimulation
(1mg ml1). One out of five independent experiments is shown. (c) Effect of BTH on tumor necrosis factor a (TNFa) and IL-8 release in NHKs after 7 hours of
stimulation with TPA (1mg ml1). (d) Effect of BTH on IL-6 and CCL27 release in NHKs after 48 hours of stimulation with TNFa (10 ng ml1). Dexamethasone (DX,
1mM) was used as reference compound. Values are expressed as mean±SEM (n¼6) **Po0.01 versus C. B, nonstimulated cells; c*, 50-fold excess of unlabeled
oligonucleotide; C, vehicle-treated stimulated cells.
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In contrast to the control stimulated cells, STAT3 was retained in
the cytoplasm of BTH-treated cells, as well as in the cytoplasm
of cells treated with 1,2,3,4,5,6-hexabromocyclohexane
(50mM), a Jak 2 inhibitor used as reference. In addition, BTH
inhibited the phosphorylation of STAT3 tyrosine 705 (Tyr705)
residue in IL-6-stimulated NHKs, as shown by western blotting
analysis (Figure 2c). This phosphorylation, carried out by the
Jak proteins, is essential for STAT3 dimerization and subse-
quent nuclear translocation and DNA binding (Aggarwal
et al., 2009). Therefore, this could be the mechanism by
which BTH inhibits STAT3 translocation.
STAT3 is a key transcriptional factor involved in the
regulation of cell proliferation (Aggarwal et al., 2009). In
accordance with its capability to inhibit STAT3 activation,
BTH impaired keratinocyte growth for 48 hours as observed
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide reduction method (Figure 2d). In these conditions,
BTH did not modify lactate dehydrogenase levels in cells
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Figure 2. 4-Benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one (BTH) impairs keratinocyte proliferation through inhibition of STAT3 phosphorylation.
(a) Immunofluorescence staining of total STAT3 (green) in 1-hour IL-6 (50 ng ml1)-stimulated normal human keratinocytes (NHKs). Blue color (406-diamidino-2-
phenylindole) stains cell nuclei. Representative images from three independent experiments. (b) Quantitative analysis of the STAT3 intracellular localization.
Results are expressed as % of total fluorescence per cell (n¼ 15) **Po0.01, versus C. (c) Western blotting of phospho-STAT3 in NHKs stimulated with IL-6
(50 ng ml1) for 30 minutes. One out of three independent experiments is shown. (d) NHK proliferation measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assay. Data are mean absorbance at 490 nm±SEM (n¼ 9) *Po0.05, **Po0.01, versus B (vehicle treated). (e) % Toxicity determined
as lactate dehydrogenase levels in the supernatants of NHKs cultured for 48 hours with BTH. NHKs in vehicle alone (B) or with Triton X-100 (Max) are set as 0%
and 100% of cytotoxicity, respectively. Data are mean±SEM (n¼ 9). B, nonstimulated cells; C, vehicle-treated stimulated cells. Bar¼ 50mm.
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supernatants in comparison with untreated cells (Figure 2e),
thus ruling out cytotoxicity as the cause of the inhibition in
cell proliferation.
BTH inhibits skin inflammation and hyperplasia in the murine
TPA–induced model
We evaluated the effect of BTH on the murine TPA-induced
epidermal hyperplasia model that reproduces certain bio-
chemical and histopathological parameters characteristic of
human psoriatic lesions (Sato et al., 2004; Amigo et al., 2007).
In this model, TPA induces pronounced skin inflammation
characterized by epidermal hyperplasia, edema, cell
infiltration, increased angiogenesis, and high production of
cytokines such as TNFa, IL-6, IL-1b, and CXCL-1 (the murine
functional analog of IL-8) (Hvid et al., 2008). In addition, the
eicosanoids prostaglandin E2 and leucotriene B4 are reported
to have an important role in the TPA-induced skin
inflammation (Murakawa et al., 2006).
Topical treatment with BTH (200 and 400mg per site)
30 minutes before TPA application (2 nmol per site for three
consecutive days) almost completely inhibited lesion forma-
tion in a dose-dependent manner. In fact, the higher dose of
BTH (400mg per site) was as effective as the reference topical
treatment with dexamethasone (200mg per site) (Figure 3a).
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Figure 3. Normalization of epidermal hyperplasia and inflammatory cell infiltration after 4-benzo[b]thiophen-2-yl-3-bromo-5-hydroxy-5H-furan-2-one (BTH)
pretreatment in 12-O-tetradecanoylphorbol-13-acetate (TPA)–induced skin inflammation. BTH, dexamethasone (DX), or vehicle (acetone) were topically applied
1 hour before TPA administration (2 nmol per site) during 3 consecutive days. (a) Macroscopic appearance of the skin at the end of the experiment. (b) Number of
infiltrating cells in representative high-power fields (HPFs) and (c) epidermal thickness of hematoxylin and eosin (H&E)–stained tissue sections as mean±SEM
(n¼ 6) **Po0.01 versus C. (d) Photomicrographs of H&E staining of skin biopsies. Bar¼200mm. (e) Immunofluorescence staining of CD3-positive cells (green,
arrows) in skin biopsies. Blue color (406-diamidino-2-phenylindole) stains cell nuclei. Bar¼ 50mm. (f) Immunohistochemical detection of cytokeratin 6 (CK6,
brown) protein in mouse skin. Bar¼ 50mm. All images are representative from one out of three mice investigated. B, acetone-treated mice; C, acetone and
TPA-treated mice.
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This beneficial effect was further confirmed by the lower
weight of the 1-cm2 punch biopsies taken from BTH-treated
mice compared with control TPA-treated mice, suggesting an
inhibition of skin edema (Figure 4a).
The histological analysis of lesion skin biopsies by hema-
toxylin and eosin staining showed a decrease of inflammatory
cell infiltrate in BTH-treated mice compared with TPA-treated
mice (Figure 3b and d), which correlated with a reduction of
myeloperoxidase (MPO) activity and leucotriene B4 levels in
skin homogenates (Figure 4b and c). In addition, BTH was
able to diminish not only the nonlymphocytic infiltrate
consisting mainly of neutrophils (Sato et al., 2004) but also
the CD3þ T-cell infiltrate, as demonstrated by fluorescent
immunohistochemistry (Figure 3e, arrows). Furthermore, BTH
treatment prevented the characteristic epidermal hyperplasia
(Figure 3c and d) and high cytokeratin 6 staining (Figure 3f)
induced by TPA, confirming the antiproliferative profile
exhibited by BTH in vitro.
Topical application of BTH reduced, in a dose-dependent
manner, the levels of TNFa, IL-6, and CXCL-1 in skin
homogenates, in agreement with the results observed in the
in vitro study. This effect was accompanied by a clear
inhibition of prostaglandin E2 and IL-1b levels, further suggest-
ing the ability of this compound to reduce inflammatory
mediators induced by TPA and regulated by NF-kB activation
(Tak and Firestein, 2001; Petersen, 2006) (Figure 4c–h).
Finally, western blotting analysis of skin homogenates
showed a TPA-induced STAT3 Tyr705 phosphorylation, which
was dose dependently inhibited by topical treatment with
BTH. In a similar manner, p65-phosphorylated NF-kB was
decreased in skin homogenates of BTH-treated mice com-
pared with control animals (Figure 4i). These results confirm
the interesting pharmacological profile of BTH as a potential
agent to treat immune disease with an inflammatory compo-
nent when applied topically to whole skin.
BTH ameliorates IMQ-induced psoriasis-like skin inflammation
We further studied the potential beneficial effect of BTH in the
murine IMQ-induced psoriasis-like skin inflammation model
in which topical application of IMQ, a Toll-like receptor 7 and
8 agonist, to the whole back of the mice during 6 days induces
skin inflammation accompanied by structural features char-
acteristic of psoriasis (van der Fits et al., 2009). In these
conditions, BTH pre-treatment ameliorated the course of the
disease and significantly reduced the development of the
scaling and erythema exclusively at the site of application,
suggesting a local effect (Figure 5a and b). Histological
analysis of punch biopsies showed a reduction of epidermal
thickening in BTH-treated skin, as seen with hematoxylin and
eosin and BrdU staining (indicative of proliferative keratino-
cytes) (Figure 5c, d and e). As expected, topical treatment
with the reference compound dexamethasone also amelio-
rated all the above-mentioned parameters. However, in
contrast to BTH, the effect of dexamethasone was extensive
to the skin beyond the delimited 3-cm2 application site,
and skin atrophy was visible throughout the whole back
(Figure 5a).
BTH pretreatment also reduced the dermal infiltrate present
in IMQ-treated mice (Figure 5c and f). This effect was further
confirmed by the lower MPO activity observed in skin
homogenates (Figure 5g). Moreover, BTH significantly
decreased IL-23 levels in skin (Figure 5h), a cytokine that
has been demonstrated to be essential for the development of
this animal model (van der Fits et al., 2009). Finally, western
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Figure 4. Topical treatment with 4-benzo[b]thiophen-2-yl-3-bromo-5-
hydroxy-5H-furan-2-one (BTH) attenuates 12-O-tetradecanoylphorbol-13-
acetate (TPA)–induced inflammation and hyperplasia through NF-jB and
STAT3 inhibition. BTH, dexamethasone (DX), or vehicle (acetone) were
topically applied 1 hour before TPA administration (2 nmol per site) during 3
consecutive days. (a) Skin edema, assayed as punch biopsy weight. (b)
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(PGE2), (e) tumor necrosis factor a (TNFa), (f) CXCL-1, (g) IL-6, and (h) IL-1b
levels determined in skin homogenates. Data represent mean±SEM (n¼6
animals). *Po0.05, **Po0.01 versus C. (i) NF-kB and STAT3 phosphorylation
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One out of three mice investigated is shown. B, acetone-treated mice; C,
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blotting analysis of skin homogenates showed that BTH was
able to impair STAT3 (Tyr705) and p65-NF-kB (Ser 536)
phosphorylation induced after IMQ treatment (Figure 5i),
corroborating the previously described mechanism of BTH.
To conclude, mice spleens were weighed at the end of the
experiment to provide a general perception on the immuno-
logical status of the animals. As expected, the administration
of IMQ produced a marked spleen hypertrophy (van der Fits
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et al., 2009), which was unaltered after topical BTH treatment
(Supplementary Figure S1 online), further suggesting a local
effect of BTH. In contrast, spleen mass from dexamethasone-
treated mice was 3-fold lower than that of healthy mice,
demonstrating systemic absorption and immunosuppressive
effect even after topical application.
DISCUSSION
Psoriasis is a chronic inflammatory skin disease characterized
by leukocyte infiltration in the dermis and epidermis, kerati-
nocyte hyperproliferation, and dilatation and growth of blood
vessels. Despite the variable course and manifestations of the
pathology, the hallmark of the skin lesions is one of inflam-
mation, involving both innate and adaptive immunity effector
mechanisms (Sano et al., 2005; Perera et al., 2012). The
introduction of new biological therapies has revolutionized
the treatment of psoriasis and has helped the understanding of
the molecular mechanisms involved in the pathogenesis of
this disease. However, biologics do not cover the needs of
those patients whose psoriasis is not severe enough to warrant
their use. These patients will greatly benefit from better topical
treatments or more effective and safer oral medications
(Williams, 2012).
In the present study, we sought to determine the antipsor-
iatic properties of BTH, a synthetic anti-inflammatory agent,
bearing the g-hidroxybutenolide moiety and derived from a
natural compound isolated from a sea sponge petrosaspongio-
lide M. BTH was selected on the basis of its ability to inhibit
NF-kB activation and ameliorate collagen-induced arthritis in
mice (Guerrero et al., 2007, 2009).
Psoriatic plaques are characterized by a chronic immune
response. In this context, keratinocytes, together with the
infiltrating cells, produce chemokines such as CCL27 and
IL-8, which recruit more leukocytes, setting up a positive
feedback loop (Perera et al., 2012). CCL27 binds to CCR10,
expressed by more than 90% of skin-infiltrating lymphocytes
(Riis et al., 2011), and IL-8 stimulates chemotaxis and degra-
nulation of neutrophils, induces angiogenesis, and modulates
HLA-DR expression and proliferation in keratinocytes
(Pietrzak et al., 2008). The expression of both chemokines is
mediated by NF-kB (Tak and Firestein, 2001; Riis et al., 2011),
thereby suggesting a pivotal role of this transcription factor in
the inflammatory events driving the conversion of pre-
psoriatic skin to psoriatic plaques. Our results demonstrate
that BTH strongly prevents the release of both chemokines,
most likely through the inhibition of NF-kB transcriptional
activity in stimulated keratinocytes, suggesting that this
molecule could exert an inhibitory effect on skin infiltration.
This hypothesis was confirmed by the in vivo studies, in which
topical administration of BTH decreased edema and leukocyte
recruitment in mouse skin. In this regard, immunofluorescence
staining showed a reduction in CD3þ T-cell infiltrate. In
addition, the decrease in CXCL-1 and leucotriene B4 levels, as
well as MPO activity, in skin homogenates of BTH-treated
mice was consistent with reduced recruitment of neutrophils,
which constitute the predominant infiltrating cell type in the
TPA-induced hyperplasia model (Ikai, 1999; Sato et al., 2004).
One of the primary events in developing psoriatic lesions is
the perivascular accumulation of neutrophils and their influx
into the epidermis (Bos et al.,2005). In these preliminary
stages, their phagocytic reactions cause oxidative damage that
initiates the expression of redox sensitive transcription factors
such as NF-kB (Briganti and Picardo, 2003). Furthermore,
neutrophils and mast cells have been recently identified as the
major source of IL-17 in human skin (Lin et al., 2011).
Therefore, BTH could impair skin inflammation in psoriatic
plaques at the early stages by blocking epidermal activation
dependent on neutrophils. These results were corroborated by
the decrease in cell infiltration and MPO activity observed in
the IMQ model.
TNFa is among the best-characterized inducers of NF-kB
activity, and a crucial link between high levels of TNFa and
NF-kB activation has been found in psoriatic patients (Lizzul
et al., 2005). It has been postulated that TNFa produced
locally in psoriatic lesions creates a positive feedback loop
that amplifies and sustains the inflammatory process within
plaques (Banno et al., 2004; Quivy and Van Lint, 2004). BTH
inhibited both NF-kB activation and TNFa release in vitro and
in vivo, suggesting an inhibitory effect on this feedback loop.
In fact, the downregulation of this transcriptional factor may
be the cause of the decrease of all the other cytokines
measured in skin samples, as their transcription is dependent
on NF-kB activation (Perera et al., 2012). It is interesting to
note that NF-kB is a major contributor to the production of
chemotactic molecules by keratinocytes even when TNFa is
downregulated (Cataisson et al., 2005). Therefore, BTH could
provide a therapeutic benefit in skin inflammatory disorders
preventing leukocyte accumulation when TNFa antagonists
are ineffective.
STAT3 is a main player in cutaneous inflammatory diseases,
as well as in normal keratinocyte function (Sano et al., 2005).
Increased phosphorylation of STAT3 has been observed in
lesional skin and many of the proinflammatory cytokines
involved in the pathogenesis of psoriasis, such as IL-6 and
the IL-20 subfamily, signal through STAT3. As a consequence,
it has been postulated that the cytokine/growth factor profile
associated with psoriasis converges, in part, on Jak/STAT3
signaling in epidermal keratinocytes (Miyoshi et al., 2011).
Actually, several Jak inhibitors are being tested as new
possible therapeutic agents for the treatment of this skin
disease with promising results (Boy et al., 2009; Chang
et al., 2009; Fridman et al., 2011). Our in vitro studies show
the ability of BTH to impair STAT3 nuclear translocation by
blocking its phosphorylation in the Tyr705 residue. These
results suggest that BTH could act through Jak inhibition, as
Jak proteins are the main conductors of this modification after
a cytokine challenge (Aggarwal et al., 2009). As cytokine
receptors can recruit two Jak family members (Jak1, Jak2, Jak3,
or Tyk2) into signaling complexes, further studies are needed
in order to completely characterize the mechanism and
specificity of BTH at this level. In addition, BTH inhibited
IL-6 release, one of the main STAT3 activators, after a 48-hour
TNFa challenge. Furthermore, it impaired keratinocyte pro-
liferation in vitro and in both murine models tested, as seen by
the decreased epidermal thickness and lower expression of
cytokeratin 6 and BrdU incorporation in skin sections. It is
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worth noting that this effect on the epidermal turnover in vivo
could be due to the decreased inflammatory milieu apparent
from the lower levels of mediators determined on skin
biopsies.
Recently, topical administration of IMQ, a ligand for Toll-
like receptors 7 and 8, was reported as a novel mouse model
of psoriasis (van der Fits et al., 2009). In this model, highly
dependent on IL-23, BTH was able to ameliorate the course of
the disease, resulting in normalization of skin inflammation
and keratinocyte proliferation. More interestingly, in addition
to its inhibitory effect on NF-kB and STAT3 activation, BTH
was able to reduce IL-23 levels in skin homogenates. The
pivotal role of this cytokine, which drives the development of
Th17 cells, in the pathogenesis of psoriasis has been robustly
confirmed by the success of the highly efficient biological
therapies targeted against IL-23 (van der Fits et al., 2009;
Yeilding et al., 2012). As STAT3 is the main factor in the IL-23
signaling pathway (Di Cesare et al., 2009), the reduction of
this cytokine by BTH could contribute to the inhibitory effect
of this compound on STAT3 activation in vivo, providing
insights to further investigate the effect of this molecule in
other cellular types involved in the IL-23/Th17 axis.
Given the acute nature of the animal models used in the
present study, we cannot fully predict the effectiveness of BTH
on the chronic treatment of established psoriatic plaques.
However, the ability of BTH to abolish NF-kB and STAT3
signaling and to decrease IL-23 levels suggests that it could
also be beneficial in the treatment of the chronic disease, as
these are some of the main orchestrators of the immune
response that sustains the chronic psoriatic process. Further-
more, the fact that BTH seems to exert its beneficial effect
locally in the area of application could provide a therapeutic
advantage with respect to the systematically immunosuppres-
sive effect of topical dexamethasone. However, further studies
will be needed to confirm the complete pharmacokinetic
profile of this compound after topical application.
In conclusion, the results of our study suggest that BTH
would be suitable for epicutaneous application, as topical
administration is often more suitable for the treatment of mild-
to-moderate psoriasis. We have demonstrated that this syn-
thetic compound diminishes two major signaling cascades
involved in the pathogenesis of autoimmune skin diseases.
Our data suggest that BTH efficiently penetrates the epidermis,
where it blocks NF-kB and STAT3 phosphorylation, leading to
normalization of lesional skin inflammation and hyperplasia.
The inhibition of both signaling pathways by BTH in the skin
could be responsible for the decrease in the production of
proinflammatory cytokines, chemokines, and adhesion mole-
cules known to have a role at both the initial stages of lesion
formation and the maintenance of the chronic inflammatory
state. In addition, the pleiotropic effect of BTH could be of
special interest, since its effects on multiple cell types provide
a potential advantage over antibodies targeted against specific
cytokines or cell types. In summary, we conclude that BTH has
a great potential as an antipsoriatic agent for the treatment of
inflammatory skin diseases. Moreover, the interesting pharma-
cological profile and singular structural features of BTH make
this compound a promising candidate for future drug research.
MATERIALS AND METHODS
Isolation, culture, and stimulation of primary human
keratinocytes
Foreskins from healthy young donors were the source of primary
human keratinocytes. All protocols and procedures were approved by
the local ethics committee and carried out according to the Declara-
tion of Helsinki Principles. Patient consent for experiments was not
required because Spanish laws consider human tissue left from
surgery as discarded material. Isolation of keratinocytes was per-
formed by sequential digestion with dispase and trypsin, as described
previously (Andres et al., 2013). Cells were grown in Defined
Keratinocyte-SFM (Invitrogen, Carlsbad, CA) and were used between
passages 1 and 3. Before the experiments, the medium was replaced
with growth factor–free keratinocyte medium, and the cells were
incubated for 24 hours before stimulation.
Before the addition of the stimulus, keratinocyte medium was
renewed and the cells were subjected to a 30-minute pretreatment
with BTH (Cayman Chemical, Ann Arbor, MI) or reference molecules
such as dexamethasone (1mM), MG-132 (1mM) (both from Sigma-
Aldrich, St Louis, MO), and a Jak2 Inhibitor ‘‘1,2,3,4,5,6-hexabro-
mocyclohexane’’ (50mM) (Calbiochem, San Diego, CA). Controls
contained an equal volume of vehicle (absolute ethanol, 1% vol/vol).
Finally, cells were stimulated with either IL-6 (50 ng ml 1) or TNFa
(10 ng ml 1) from R&D Systems (Abingdon, UK) or TPA (1mg ml 1)
from Sigma-Aldrich.
Determination of cytokine release and NF-jB/STAT3 activation
in vitro
After the specified agent treatment and stimulation time, supernatants
were collected and the levels of CCL27, TNFa (R&D Systems), IL-6,
and IL-8 (eBioscience, San Diego, CA) were measured using ELISA
assays according to the standard manufacturer protocols. In addition,
cells were lysed in order to obtain nuclear extracts where NF-kB–
DNA binding was assessed by electrophoretic mobility shift assay, as
described previously (Andres et al., 2013). Parallely, total cell lysates
were obtained and western blotting was performed with a specific
antibody against pSTAT3 Tyr705 (Cell Signaling Technology, Beverly,
MA), as described elsewhere (Andres et al., 2013). In another set of
experiments, cells were fixed, permeabilized, and inmunostained using
polyclonal rabbit anti-STAT3 (Cell Signaling Technology) followed by
Alexa Fluor 488 secondary antibody (Invitrogen, Carlsbad, CA)
(Andres et al., 2013). Detailed description of these procedures can
be found in Supplementary Materials online.
Cell proliferation and cytotoxicity assay
Keratinocytes were grown in complete keratinocyte growth medium
in the presence of BTH for 48 hours. Cell density was determined by
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
uptake method as previously described (Borenfreund et al., 1988).
Product toxicity was assessed by measuring lactate dehydrogenase
release in the culture supernatants (Miyoshi et al., 2011).
Animals
Mice were obtained from Janvier (Le Genest St Isle, France). All
studies were conducted in accordance with European Union regula-
tions for the handling and use of laboratory animals. Animal protocols
were approved by the Institutional Animal Care and Use Committee
of the University of Valencia.
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TPA-induced epidermal hyperplasia model
A total of 20ml of 100mM TPA (2 nmol per site) or vehicle (acetone)
was applied to 1 cm2 of the shaved dorsal area of female Swiss CD-1
mice (25–30 g) using a micropipette. At 1 hour before the inflamma-
tory challenge, BTH (200 or 400mg per site), dexamethasone (200mg
per site), or vehicle (acetone) was topically administered to the same
area. This procedure was repeated during three consecutive days.
At the end of the experiment (day 4), mice were killed by cervical
dislocation and 1-cm2 punch biopsies were taken from the
treated dorsal skin and weighed in order to measure edema
(Amigo et al., 2008). Biopsies were then fixed in formalin for
histological study as described previously (Blumberg et al., 2010).
Alternatively, biopsies were frozen in liquid N2 and homogenized.
Cytokines in skin homogenates were measured by ELISA according
to the manufacturer’s specifications, and eicosanoids and MPO
were determined as described previously (Amigo et al., 2007).
Full description of these procedures can be found in Supplementary
Materials online.
IMQ-induced psoriasis-like skin inflammation in mice
Female mice BALB/c (8–11 weeks) received a daily topical dose of
62.5 mg of commercially available IMQ cream (Aldara 5%; Meda AB,
Solna, Sweden) on the dorsal and lumbar areas of the shaved back for
6 consecutive days, as described previously (van der Fits et al., 2009).
Similarly, a vehicle cream (Vaselina Pura, Laboratorios Rida,
Valencia, Spain) was applied to the IMQ-untreated mice.
1 hour before the cream application, BTH (400mg per site),
dexamethasone (200mg per site), or vehicle (acetone) were topically
administered to a delimited area of 3 cm2. At the end of the experi-
ment, mice were killed by cervical dislocation and 1-cm2 punch
biopsies were taken from the treated dorsal skin and stored at  70 1C
for subsequent homogenization or fixed in formalin for histological
study carried out as described previously (van der Fits et al., 2009).
Detailed description can be found in Supplementary Materials online.
Alternatively, mice were killed at day 3 in order to study STAT3 and
NF-kB activation. To measure the severity of the disease, an objective
scoring system was developed based on the clinical Psoriasis Area
and Severity Index, as described previously (van der Fits et al., 2009),
and was performed blindly by an independent investigator.
Statistical analysis
The level of statistical significance was determined by analysis of
variance (ANOVA) followed by Dunnett’s t-test for multiple compar-
isons using the GraphPad Prism 4 software (GraphPad Software
San Diego, CA). Significance was assumed at Po0.05.
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